ImmunityBio, Inc.

ImmunityBio, Inc. is a biotechnology company that develops and sells advanced immunotherapies designed to activate a patient's immune system for long-lasting protection against cancer and infectious diseases. The company's development platforms create biologic products and product candidates, including cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. These platforms have produced initial therapeutic agents intended for clinical trials in both liquid and solid tumors. ImmunityBio's primary biologic product candidate is Anktiva, an FDA-approved immunotherapy. Anktiva is used in combination with bacillus calmette-guérin (BCG) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer that includes carcinoma in situ, with or without papillary tumors. Another key product candidate is 3M-052, which is a synthetic TLR7/8 agonist, along with its formulations and related technology. The company collaborates with the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd. It also holds license agreements with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is headquartered in San Diego, California.